Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
7.07
Oct 30 • 3:59 PM ET Dollar change-0.24 Percentage change(-3.28%)
Aftermarket Close
7.07
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
-
Market Cap
28.50M
Enterprise Value
17.63M
Income
-5.24M
Sales
69.39M
Book/sh
8.83
Cash/sh
6.15
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
157
IPO
Jan 27, 1998
P/E
-
Forward P/E
-
PEG
-
P/S
0.41
P/B
0.80
P/C
1.15
P/FCF
18.51
EV/EBITDA
-
EV/Sales
0.25
Quick Ratio
3.00
Current Ratio
3.25
Debt/Eq
0.40
LT Debt/Eq
0.29
Option/Short
No / Yes
EPS (ttm)
-1.37
EPS next Y
-0.20
EPS next Q
-0.18
EPS this Y
32.67%
EPS next Y
79.70%
EPS next 5Y
48.37%
EPS past 3/5Y
56.86% 49.20%
Sales past 3/5Y
-1.65% 2.17%
EPS Y/Y TTM
-109.07%
Sales Y/Y TTM
-21.12%
EPS Q/Q
22.91%
Sales Q/Q
10.63%
Insider Own
16.37%
Insider Trans
-0.15%
Inst Own
8.49%
Inst Trans
-1.60%
ROA
-9.32%
ROE
-15.53%
ROIC
-11.21%
Gross Margin
17.71%
Oper. Margin
-6.52%
Profit Margin
-7.55%
SMA20
-5.64%
SMA50
-10.64%
SMA200
-14.14%
Trades
Shs Outstand
3.97M
Shs Float
3.37M
52W High
12.90 -45.19%
52W Low
4.89 44.73%
Volatility
6.58% 5.96%
ATR (14)
0.46
RSI (14)
40.99
Beta
1.73
Rel Volume
1.54
Avg Volume
25.75K
Volume
39,545
Perf Week
1.87%
Perf Month
-17.50%
Perf Quarter
-2.21%
Perf Half Y
-20.40%
Perf YTD
-15.18%
Perf Year
-34.54%
Perf 3Y
-58.17%
Perf 5Y
-88.02%
Perf 10Y
-98.87%
Prev Close
7.31
Price
7.07
Change %
-3.28%
Consensus
Strong Buy
Avg. Price Target
$20.00
Implied Upside
+182.9%
Analysts14incl. previous ratings
Rating Distribution10 Buy · 1 Hold · 3 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Nov 14, 2024Initiated
RRodman & Renshaw
Buy$5-29.3%
Jun 24, 2019Initiated
PPiper Jaffray
Overweight$10+41.4%
May 13, 2019Initiated
HH.C. Wainwright
Buy$11+55.6%
Nov 08, 2016Downgrade
BAC logoBBofA/Merrill
Neutral → Underperform
Mar 01, 2016Downgrade
SF logoSStifel
Buy → Hold
Aug 13, 2015Initiated
MS logoMMorgan Stanley
Underweight$7-1.0%
Jan 27, 2015Reiterated
OPY logoOOppenheimer
Outperform$24 → $26+267.8%
Jan 07, 2015Initiated
OPY logoOOppenheimer
Outperform$24+239.5%
Aug 14, 2014Initiated
FFBR Capital
Underperform$6-15.1%
Dec 19, 2013Initiated
CChardan Capital Markets
Buy$22+211.2%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Strobeck MarkPresident and CEOOct 01 '26Sale8.421,0008,42061,349Oct 05 04:03 PM
Strobeck MarkOfficerOct 01 '26Proposed Sale8.401,0008,400Oct 01 03:29 PM
Hunter HeatherChief Operating OfficerJan 02 '26Sale0.842,8682,396132,523Jan 05 04:15 PM
Neri JesseSVP and CFOJan 02 '26Sale0.84886740124,842Jan 05 04:13 PM
Neri JesseOfficerJan 02 '26Proposed Sale0.80886712Jan 05 09:38 AM
Hunter HeatherOfficerJan 02 '26Proposed Sale0.812,8682,318Jan 02 04:40 PM
COOPER JOHN GDirectorNov 18 '25Sale0.875,0794,419140,372Nov 18 04:26 PM
COOPER JOHN GDirectorNov 18 '25Proposed Sale0.905,0794,572Nov 18 09:54 AM
Rockwell Medical, Inc. is a biopharmaceutical company, which engages in the development of treatment for anemia, kidney disease, iron deficiency, and hemodialysis. Its products include Triferic, CitraPure, RenalPure and SteriLyte. The company was founded by Robert L. Chioini on October 25, 1996 and is headquartered in Wixom, MI.
PresidentDr. Mark Strobeck Ph.D.
Senior VP & CFOMr. Jesse Neri
Executive VPMs. Megan C. Timmins
Senior VP & COOMs. Heather H. Hunter
Controller & Principal Accounting OfficerMr. Nicholas Fanslau